Mereo BioPharma Group plc (MREO) Financials

MREO Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 34.7 million 6.1 million
March 31, 2026 40.6 million 6.6 million
Dec. 31, 2025 45.9 million 5.0 million
Sept. 30, 2025 53.6 million 7.0 million

MREO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -6.0 million 1.3 million
March 31, 2026 -4.3 million 1.6 million
Dec. 31, 2025 -7.7 million 1.5 million
Sept. 30, 2025 -7.3 million 1.7 million

MREO Net Income

No data available :(

MREO Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 30.1 million - -
March 31, 2026 36.2 million - -
Dec. 31, 2025 41.0 million - 202000
Sept. 30, 2025 48.7 million - 397000

MREO Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 160.7 million
March 31, 2026 160.4 million
Dec. 31, 2025 159.4 million
Sept. 30, 2025 160.0 million

MREO Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 1.8 million 5.2 million -
March 31, 2026 300000 4.7 million 4.0 million -
Dec. 31, 2025 1521 4.2 million 4.2 million -
Sept. 30, 2025 - 3.8 million 6.0 million -

MREO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 304488
Dec. 31, 2025 - 591144
Sept. 30, 2025 - 1000

MREO

Price: $0.32

52 week price:
0.20
2.37

Earnings Per Share: -0.19 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United Kingdom

Volume: 278100

Market Capitalization: 48.3 million

Links: